Another RIPK1 inhibitor, SIR-2446 is an oral RIPK1 inhibitor being developed by Sironax therapeutics for the treatment of AD and MS and is currently in Phase 1 clinical trials. This evidence concerns the gene RIPK1 and myeloid sarcoma.